Article

Molecular Characterization of the Enterohemolysin Gene (*ehxA*) in Clinical Shiga Toxin-Producing *Escherichia coli* Isolates

Ying Hua [1,2], Ji Zhang [3], Cecilia Jernberg [4], Milan Chromek [5], Sverker Hansson [6,7], Anne Frykman [6,7], Yanwen Xiong [8], Chengsong Wan [1], Andreas Matussek [2,9,10,11,*] and Xiangning Bai [8,12,*]

1   Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China; hying615@smu.edu.cn (Y.H.); gzwcs@smu.edu.cn (C.W.)
2   Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, 141 52 Stockholm, Sweden
3   Molecular Epidemiology and Public Health Laboratory, School of Veterinary Sciences, Massey University, Palmerston North 4100, New Zealand; jizhang.palmy@gmail.com
4   The Public Health Agency of Sweden, 171 82 Solna, Sweden; cecilia.jernberg@folkhalsomyndigheten.se
5   Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, 141 86 Stockholm, Sweden; milan.chromek@sll.se
6   Queen Silvia Children's Hospital, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden; sverker.hansson@pediat.gu.se (S.H.); anne.frykman@vgregion.se (A.F.)
7   Department of Pediatrics, Department of Pediatrics, Sahlgrenska Academy, Sahlgrenska Academy, University of Gothenburg, 416 85 Gothenburg, Sweden
8   State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; xiongyanwen@icdc.cn
9   Laboratory Medicine, Jönköping Region County, Department of Clinical and Experimental Medicine, Linköping University, 551 85 Jönköping, Sweden
10   Oslo University Hospital, 0372 Oslo, Norway
11   Division of Laboratory Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway
12   Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden
*   Correspondence: anmatu@ous-hf.no (A.M.); xiangning.bai@ki.se (X.B.)

Abstract: Shiga toxin (Stx)-producing *Escherichia coli* (STEC) is an important foodborne pathogen with the ability to cause bloody diarrhea (BD) and hemolytic uremic syndrome (HUS). Little is known about enterohemolysin-encoded by *ehxA*. Here we investigated the prevalence and diversity of *ehxA* in 239 STEC isolates from human clinical samples. In total, 199 out of 239 isolates (83.26%) were *ehxA* positive, and *ehxA* was significantly overrepresented in isolates carrying $stx_{2a} + stx_{2c}$ ($p < 0.001$) and *eae* ($p < 0.001$). The presence of *ehxA* was significantly associated with BD and serotype O157:H7. Five *ehxA* subtypes were identified, among which, *ehxA* subtypes B, C, and F were overrepresented in *eae*-positive isolates. All O157:H7 isolates carried *ehxA* subtype B, which was related to BD and HUS. Three *ehxA* groups were observed in the phylogenetic analysis, namely, group I (*ehxA* subtype A), group II (*ehxA* subtype B, C, and F), and group III (*ehxA* subtype D). Most BD- and HUS-associated isolates were clustered into *ehxA* group II, while *ehxA* group I was associated with non-bloody stool and individuals ≥10 years of age. The presence of *ehxA* + *eae* and *ehxA* + *eae* + stx_2 was significantly associated with HUS and O157:H7 isolates. In summary, this study showed a high prevalence and the considerable genetic diversity of *ehxA* among clinical STEC isolates. The *ehxA* genotypes (subtype B and phylogenetic group II) could be used as risk predictors, as they were associated with severe clinical symptoms, such as BD and HUS. Furthermore, *ehxA*, together with *stx* and *eae*, can be used as a risk predictor for HUS in STEC infections.

Keywords: Shiga toxin-producing *Escherichia coli*; enterohemolysin; *ehxA*; gene diversity; hemolytic uremic syndrome; clinical significance

Key Contribution: This study showed a high prevalence and considerable genetic diversity of enterohemolysin-encoding gene *ehxA* among clinical STEC isolates. The *ehxA* genotypes could be used as risk predictors, *ehxA* subtype B and phylogenetic group II were found to be associated with severe clinical symptoms, such as bloody diarrhea (BD) and hemolytic uremic syndrome (HUS).

1. Introduction

Shiga toxin-producing *Escherichia coli* (STEC) is an important enteric foodborne pathogen that can cause bloody diarrhea (BD), hemorrhagic colitis, and potentially fatal hemolytic uremic syndrome (HUS) in infected humans [1]. STEC is estimated to cause 2.8 million cases of enteric disease in humans per year globally [2]. Over 400 STEC serotypes have been identified, among which, O157:H7 is the most prevalent serotype and is linked to severe human illness, such as HUS [3,4]. Nevertheless, since the early 2010s, non-O157 STEC, especially the so-called "top six" serogroups (O26, O45, O103, O111, O121, and O145), have been associated with continuously increasing numbers of STEC outbreaks and may account for up to 80% of STEC infections [2,5,6]. Humans are infected through contact with infected animals or the consumption of STEC-contaminated water, vegetables, milk, or meat.

Shiga toxins (Stx_1 and Stx_2) are the main virulence factors of STEC, which can mediate a significant cytotoxic effect in human vascular endothelial cells [7]. *stx* genes are located in the genomes of Shiga-toxin-converting bacteriophages [8]. At least 15 stx_1 and stx_2 gene subtypes have been identified, among which, stx_{2a}, stx_{2c}, and stx_{2d} are more virulent than other subtypes as they are highly associated with severe clinical outcomes, such as HUS [9]. Besides Stx, *eae*-encoding intimin, which is responsible for the intimate adherence of STEC, is also a significant virulence trait of pathogenic STEC [10,11]. In addition, hemolysin-encoding genes have been regarded as STEC virulence markers [7]. So far, four different types of hemolysins have been identified, namely, alpha-hemolysin (*hlyA*), silent hemolysin (*sheA*), bacteriophage-associated enterohemolysin (*e-hlyA*), and plasmid-carried enterohemolysin (*ehxA*) [12]. Enterohemolysin displays hemolytic activity that enables STEC to be observed on washed sheep blood agar, which is commonly used as a phenotypic indicator of STEC strains [13,14]. It is noteworthy that *ehxA* is prevalent in STEC strains and is closely associated with isolates causing diarrheal disease and HUS [15].

Enterohemolysin belongs to the repeats in toxin (RTX) family, which has a pore-forming capacity [16]. *ehxA* is located on a large virulence plasmid and its nucleic acid sequence has about 3000 base pairs [17]. The presence of *ehxA* has a close association with *stx*, thus it is proposed as an epidemiological marker for the rapid characterization of STEC strains [13]. For example, in the U.S. Food and Drug Administration *E. coli* Identification (FDA-ECID) microarray, *ehxA* is included as one of the genetic markers for the rapid characterization of STEC isolates [18]. Six genetically distinct *ehxA* subtypes (A to F) have been described in *E. coli* by using PCR in combination with restriction fragment length polymorphism (RFLP) analysis [12]. STEC *ehxA* subtypes differ significantly among strains isolated from different sources. Subtypes A and C are mostly found in animal isolates, where subtype A is detected in food-associated strains and subtype C is commonly found in clinical strains [12]. However, such data are limited; the correlation between *ehxA* subtypes and strains sources, as well as the clinical relevance, remains to be further elucidated.

A recent study in Sweden showed that almost all of the *eae*-positive isolates, except one, harbored *ehxA*, and the coexistence of *ehxA* and *eae* was shown to be associated with BD [19]. In a previous study, only 10.9% of isolates carried *eae* among 138 *ehxA*-positive non-O157 STEC isolates from human, animal, and food sources in China, and 61.54% of these were clinically relevant [20]. The aim of this study was to investigate the prevalence and genetic diversity of the *ehxA* gene, its correlation with serotypes, and the presence of *stx* and *eae*. Furthermore, we aimed to assess the association between *ehxA* subtypes and disease severity.

2. Results

2.1. Distribution of ehxA in the Clinical STEC Isolates

Among the 239 STEC strains isolated in Sweden, *ehxA* was identified in 199 (83.26%) isolates. Fifty-three (26.63%) of the *ehxA*-positive isolates were from patients with HUS, 47 (23.62%) were from patients with BD, and 99 (49.75%) were from individuals with NBS (non-bloody stool). All O157:H7 isolates were *ehxA* positive and the majority (45/65, 69.23%) were also $stx_{2a} + stx_{2c}$ positive. The majority of the *eae*-positive STEC isolates (166 of 173, 95.95%) carried *ehxA*. *ehxA* was overrepresented in isolates that carried $stx_{2a} + stx_{2c}$ ($p < 0.001$) and *eae* ($p < 0.001$). The presence of *ehxA* was significantly associated with BD and O157:H7 (Table 1). However, no association was observed between the presence of *ehxA* and the duration of bacterial shedding, the age of the patients, or HUS (Table S1).

Table 1. Prevalence of the *ehxA* gene in 239 STEC isolates from Shiga toxin-producing *E. coli* (STEC)-positive individuals [a].

| *ehxA* | No. (%) | | *p*-Value | No. (%) | | *p*-Value | No. (%) | | *p*-Value | No. (%) | | *p*-Value |
	BD (51)	NBS (128)		O157:H7 (65)	Non-O157 (174)		$stx_{2a} + stx_{2c}$ (48)	Non-$stx_{2a} + stx_{2c}$ (191)		*eae* + (173)	*eae* − (66)	
Positive	47 (92.16)	99 (77.34)	0.021 *	65 (100.00)	134 (77.01)	<0.001 *	48 (100.00)	151 (79.06)	<0.001 *	166 (95.95)	33 (50.00)	<0.001 *
Negative	4 (7.84)	29 (22.66)		0 (0.00)	40 (22.99)		0 (0.00)	40 (20.94)		7 (4.05)	33 (50.00)	

HUS: hemolytic uremic syndrome; BD: bloody diarrhea; NBS: non-bloody stool. [a] The associations were analyzed between the presence of *ehxA* and clinical symptoms (HUS and non-HUS; BD and NBS), age groups (<10 years of age; ≥10 years of age), duration of bacterial shedding (long: >24 days; short: ≤24 days), serotypes (O157 and Non-O157), *stx* subtypes, the presence of *eae*; only differences showing statistical significance were shown. * Statistically significant difference.

2.2. Diversity of ehxA and Its Correlation to Serotypes and the stx and eae Genes

Thirty unique *ehxA* sequences (genotypes GT1 to GT30) were identified among the 199 *ehxA* positive STEC isolates. The nucleotide similarities of *ehxA* gene sequences in this study ranged from 95.79 to 100%. Five distinct subtypes (A, B, C, D, F) were found, out of which, subtype C (76, 38.19%) was the most predominant subtype, followed by *ehxA* subtype B (65, 32.66%) and *ehxA* subtype A (29, 14.57%). In addition, subtype C showed greater genetic diversity than other subtypes. All isolates carrying subtypes B, C, or F were *eae* positive, with the exception of two *ehxA* subtype C isolates (Table 2). Interestingly, all *ehxA* subtype A and D isolates were *eae* negative and subtype B was only found in O157:H7 isolates (Table 2). Other *ehxA* subtypes were represented within different serotypes: *ehxA* subtype C was linked to O121:H19 and O26:H11 strains (Table S2) and subtype F mainly belonged to O103:H2 isolates (Table 2). The presence of *ehxA* + *eae* (Table 3) and *ehxA* + *eae* + stx_2 (Table S3) was statistically associated with O157:H7 isolates. The presence of stx_1 and its subtype stx_{1a} was statistically associated with *ehxA* subtype F, while the presence of stx_2 and its subtype $stx_{2a} + stx_{2c}$ was linked to *ehxA* subtype B (Table 4).

Table 2. Characteristics of *ehxA*-positive STEC isolates.

ehxA Subtype	No. of Isolates	Genotype (No.)	Group (No.)	*eae* (No.) Positive	Negative	Serotype (No.)	*stx* Subtype (No.)	Symptoms (No.)	Age Group (No.)	Duration of Bacterial Shedding (No.)
A	29	GT1 (3), GT2 (14), GT5 (1), GT6 (2), GT11 (3), GT12 (1), GT16 (2), GT17 (1), GT20 (2)	I (29)	0	29	O91:H21 (3), O113:H4 (2), O146:H21 (2), O150:H10 (4), O128ab:H2 (2), O4:H16 (1), O117:H8 (2), O91:H14 (2), O117:H8 (2), O185:H28 (1), O5:H19 (1), Ont:H4 (1), O78:H4 (2), O175:H21 (1), O183:H18 (2), O126:H20 (1), O163:H19 (2)	stx_{2d} (5), stx_{2b} (6), stx_{1c} (6), stx_{2a} (1), $stx_{1c} + stx_{2b}$ (5), $stx_{1a} + stx_{2b}$ (2), $stx_{1a} + stx_{2a}$ (4), $stx_{1a} + stx_{2d}$ (2)	NBS (25), BD (4)	<10 years (11), ≥10 years (18)	Short (7), long (9), NA (13)
B	65	GT3 (46), GT18 (1), GT29 (18)	II (65)	65	0	O157:H7 (65)	$stx_{2a} + stx_{2c}$ (45), stx_{2c} (9), stx_{2a} (2), $stx_{1a} + stx_{2c}$ (9)	HUS (32), BD (19), NBS (14)	<10 years (18), ≥10 years (16), NA (31)	Short (17), long (8), NA (40)
C	76	GT7 (2), GT8 (25), GT9 (1), GT13 (1), GT14 (2), GT15 (1), GT19 (1), GT21 (3), GT22 (3), GT23 (1), GT28 (1), GT30 (35)	II (76)	74	2	O84:H2 (1), O98:H21 (1), O121:H19 (25), O26:H11 (35), O111:H8 (4), O180:H2 (1), O165:H25 (4), O145:H28 (3), O103:H8 (1), O103:H2 (1)	stx_{1a} (36), stx_{2a} (33), $stx_{1a} + stx_{2a}$ (4), $stx_{2a} + stx_{2c}$ (3)	HUS (21), BD (20), NBS (35)	<10 years (36), ≥10 years (21), NA (19)	Short (21), long (19), NA (36)
D	2	GT26 (1), GT27 (1)	III (2)	0	2	O187:H28 (1), O136:H12 (1)	stx_{2g} (1), stx_{2a} (1)	NBS (2)	<10 years (1), ≥10 years (1)	Short (2)
F	27	GT4 (20), GT10 (3), GT24 (2), GT25 (2)	II (27)	27	0	O103:H2 (18), O123:H2 (3), O71:H2 (1), O177:H25 (3), O5:H9 (2)	stx_{1a} (24), stx_{2c} (24)	NBS (23), BD (4)	<10 years (21), ≥10 years (6)	Short (12), long (13), NA (2)

Table 3. Association between the presence of *ehxA* + *eae* and clinical symptoms, age groups, and serotypes.

ehxA + *eae*	No. (%)		*p*-Value	No. (%)		*p*-Value	No. (%)		*p*-Value
	Non-HUS (146)	HUS (53)		<10 Years of Age (87)	≥10 Years of Age (62)		O157:H7 (65)	Non-O157 (134)	
+	114 (78.08)	52 (98.11)	<0.001 *	75 (86.21)	42 (67.74)	<0.001 *	65 (100.00)	101 (75.37)	<0.001 *
−	32(21.92)	1 (1.89)		12 (13.79)	20 (32.26)		0 (0.00)	33 (24.63)	

* Statistically significant difference.

Table 4. Association between *stx* subtypes and *ehxA* subtypes [a].

stx Subtype	*ehxA* Subtype (No. Isolates)		*p*-Value	BH-Corrected *p*-Value
stx₁	**F (27)**	**Non-F (172)**		
+	24 (88.89)	42 (24.12)	<0.001 *	<0.001 *
−	3 (11.11)	130 (75.58)		
stx₁ₐ	**F (27)**	**Non-F (172)**		
+	24 (88.89)	36 (20.93)	<0.001 *	<0.001 *
−	3 (11.11)	136 (79.07)		
stx₂	**B (65)**	**Non-B (134)**		
+	56 (86.15)	51 (38.06)	<0.001 *	<0.001 *
−	9 (13.85)	83 (61.94)		
stx₂ₐ + stx₂c	**B (65)**	**Non-B (134)**		
+	45 (69.23)	3 (2.24)	<0.001 *	<0.001 *
−	20 (30.77)	131 (97.76)		

[a] The association was analyzed between the *stx* subtypes and *ehxA* subtypes; only differences showing statistical significance were shown. The *stx* subtypes and *ehxA* subtypes (number of isolates) were indicated in bold. * Statistically significant difference. BH: Benjamini–Hochberg.

A neighbor-joining tree was generated using 30 unique *ehxA* sequences from this study and 26 reference *ehxA* sequences that were reported previously. Three phylogenetic groups were identified, namely, group I (*ehxA* subtype A), where all isolates were *eae* negative; group II (*ehxA* subtype B, C, F), where all isolates were *eae* positive; group III (*ehxA* subtype D) containing only two *eae*-negative isolates (Figure 1).

2.3. ehxA Subtypes and Phylogenic Groups in Correlation with Clinical Variables and the Presence of eae

ehxA subtype B was overrepresented in BD- and HUS-associated isolates. Accordingly, *ehxA* group II was statistically associated with BD and HUS. *ehxA* subtype A and *ehxA* group I were statistically associated with NBS and individuals ≥10 years of age; *ehxA* subtype F and *ehxA* group II were significantly linked to individuals <10 years of age; however, these differences had no statistical significance after Benjiamini–Hochberg corrections (Table 5). *ehxA* subtype B and *ehxA* group II were statistically associated with O157:H7 strains ($p < 0.001$) (Table 5). No association was observed between the *ehxA* subtype/phylogenetic group and the duration of bacterial shedding (data not shown). The presence of *ehxA* + *eae* (Table 3) and *ehxA* + *eae* + *stx₂* (Table S3) was statistically associated with HUS. In addition, the presence of *ehxA* + *eae* was overrepresented in isolates from individuals <10 years of age (Table 3).

Figure 1. Phylogenetic relationships of the 30 unique *ehxA* sequences identified in this study and 26 reference sequences of six *ehxA* subtypes that were downloaded from GenBank based on the neighbor-joining method. The 26 reference sequences of six *ehxA* subtypes (A to F) are indicated in bold, the strain name of each reference sequence is shown, followed by the accession number in parentheses, the serotype, and the *ehxA* subtype. For the 30 unique *ehxA* sequences in this study, the representative isolate of each genotype is shown, followed by the corresponding *ehxA* genotype (number of isolates), serotypes (number of isolates), symptoms (number of isolates), and *ehxA* subtype. The phylogenetic groups of *ehxA* sequences are labeled in different colors. Bootstrap values above 50% are shown at the branch points. The scale bar indicates the genetic distance.

Table 5. Association between the *ehxA* subtypes/groups and symptoms, age group, serotypes, and the presence of *eae*.

ehxA Subtype	No. Isolates	NBS (99) Pos	NBS Prevalence	BD (47) Pos	BD Prevalence	*p*-Value	BH-Corrected *p*-Value	Non-HUS (146) Pos	Prevalence	HUS (53) Pos	Prevalence	*p*-Value	BH-Corrected *p*-Value	<10 Years (87) Pos	Prevalence	≥10 Years (62) Pos	Prevalence	*p*-Value	BH-Corrected *p*-Value	O157:H7 (65) Pos	Prevalence	non-O157 (134) Pos	Prevalence	*p*-Value	BH-Corrected *p*-Value	Positive (166) Pos	Prevalence	Negative (33) Pos	Prevalence	*p*-Value	BH-Corrected *p*-Value
A	29	25	25.25%	4	8.51%	0.018 *	0.535	29	19.86%	0	0.00%	<0.001 *	0.013 *	11	12.64%	18	29.03%	0.013 *	0.383	0	0.00%	29	21.64%	<0.001 *	0.002 *	0	0.00%	29	87.88%	<0.001 *	<0.001 *
B	33	14	14.14%	19	40.43%	<0.01 *	0.012 *	33	22.60%	32	60.38%	<0.001 *	<0.001 *	18	20.69%	16	25.81%	0.463	1.000	65	100.00%	0	0.00%	<0.001 *	<0.001 *	65	39.16%	0	0.00%	<0.001 *	<0.001 *
C	55	35	35.35%	20	42.55%	0.402	1.000	55	37.67%	21	39.62%	0.802	1.000	36	41.38%	21	33.87%	0.353	1.000	0	0.00%	76	56.72%	<0.001 *	<0.001 *	74	44.58%	2	6.06%	<0.001 *	0.001 *
D	2	2	2.02%	0	0.00%	0.327	1.000	2	1.37%	0	0.00%	0.392	1.000	1	50.00%	1	50.00%	0.809	1.000	0	0.00%	2	1.49%	0.32	1.000	0	0.00%	2	6.06%	0.027 *	0.810
F	27	23	23.23%	4	8.51%	0.032	0.969	27	18.49%	0	0.00%	<0.001 *	0.023 *	21	24.14%	6	9.68%	0.024 *	0.717	0	0.00%	27	20.15%	<0.001 *	0.003 *	27	16.27%	0	0.00%	0.013 *	0.381
ehxA **Group**																															
Group I	29	25	25.25%	4	8.51%	0.018 *	0.321	29	19.86%	0	0.00%	<0.001 *	0.008 *	11	12.64%	18	29.03%	0.013 *	0.230	0	0.00%	29	21.64%	<0.001 *	0.001 *	0	0.00%	29	87.88%	<0.001 *	<0.001 *
Group II	115	72	72.73%	43	91.49%	<0.01 *	0.173	115	78.77%	53	100.00%	<0.001 *	0.005 *	75	86.21%	43	69.35%	0.012 *	0.225	65	100.00%	103	76.87%	<0.001 *	<0.001 *	166	100.00%	2	6.06%	<0.001 *	<0.001 *
Group III	2	2	2.02%	0	0.00%	0.327	1.000	2	1.37%	0	0.00%	0.392	1.000	1	50.00%	1	50.00%	0.809	1.000	0	0.00%	2	1.49%	0.322	1.000	0	0.00%	2	6.06%	0.027 *	0.486

HUS: hemolytic uremic syndrome; BD: bloody diarrhea; NBS: non-bloody stool. Age groups (<10 years of age; ≥10 years of age). Pos: number of positive isolates. * Statistically significant difference.

3. Discussion

Shiga toxin and intimin have been widely investigated as vital virulence factors of STEC [21]. In addition, enterohemolysin (*ehxA*) has emerged as a possible marker for the identification of specific STEC strains, such as O26, O157, O145, and O103, which are highly related to severe clinical symptoms, including BD and HUS [13,17,22,23]. The presence of *ehxA* was shown to be a useful epidemiological marker for the presence of Stx [12,14]. However, the role of *ehxA* in STEC pathogenicity and the association between *ehxA* and other key STEC virulence factors, such as *stx* and *eae*, have not been fully elucidated. Here, we systematically investigated the prevalence of *ehxA* in human clinical STEC isolates in Sweden and analyzed the association between *ehxA* and clinical symptoms, as well as the bacterial features. We found that *ehxA* was present in 83.26% of all clinical STEC isolates in this study. The majority of the *eae*-positive isolates also carried the *ehxA* gene, while only 50% of the *eae*-negative isolates carried *ehxA*. This was in line with a previous study, where *ehxA* was divided into two major phylogenetic clusters based on the presence or absence of *eae* [24]. *ehxA* was also shown to have a strong link with *eae*-positive atypical EPEC strains that were isolated from cattle and sheep [17]. Notably, the presence of *ehxA* was statistically associated with O157:H7, $stx_{2a} + stx_{2c}$, and BD, suggesting that *ehxA* could be included as a virulence marker in clinical diagnostics to predict highly pathogenic STEC strains.

The phylogeny analysis showed that *ehxA*-positive STEC isolates were divided into three groups, as described in a previous study [20]. *ehxA* subtypes B, C, and F were assigned to group II, among which, 98.8% carried the *eae* gene. *ehxA* subtypes A and D were assigned to groups I and III, respectively, which were all *eae* negative. This was in concordance with other studies [12,17], indicating that *ehxA* subtypes B, C, and F were closely associated with *eae*-positive strains. *ehxA* subtype C was the most predominant among the five subtypes, in accordance with a previous study demonstrating that clinical isolates mainly carried *ehxA* subtype C [12]. Importantly, we found that all O157:H7 isolates carried *ehxA* subtype B, which was consistent with a previous study [12]. This may also explain the associations we observed between *ehxA* subtype B and stx_2, BD, and HUS, since O157:H7 strains often carry stx_2 and are highly associated with BD and HUS [19]. In addition, these results suggest that *ehxA* subtype B could indicate a higher virulence than other subtypes. Correspondingly, *ehxA* group II, which included *ehxA* subtype B, was found to be statistically associated with O157:H7, BD, and HUS. *ehxA* group I and subtype A was linked to NBS and individuals ≥10 years of age, while *ehxA* subtype F was associated with individuals <10 years of age, although these differences did not reach statistical significance after Benjiamini–Hochberg corrections. These data indicated that isolates belonging to *ehxA* group II were highly pathogenic; *ehxA* phylogenic grouping could thus be used in the risk assessment of STEC infection.

Serotype O157:H7, stx_2 subtype stx_{2a}, and virulence genes *eae* and *ehxA* were often found to be more common in HUS patients [15,25,26]. The combination of stx_2 and *eae* could increase the risk of developing severe clinical outcomes [27,28]. Here, we found that the presence of *ehxA* + *eae* and *ehxA* + *eae* + stx_2 were statistically associated with HUS and O157:H7, indicating that the coexistence of more than one virulence factor could be associated with more severe clinical outcomes in STEC infections. In addition, the coexistence of *ehxA* and *eae* was linked to isolates from individuals <10 years of age.

There were some limitations in our study. First, we did not test the enterohemolytic phenotypes of the *ehxA*-positive clinical STEC isolates in this study. Previous studies showed that some *ehxA*-positive serotypes, for instance, O157:H$^-$ [29] and O111:H$^-$ [30], showed no enterohemolytic phenotype on washed sheep blood agar. Additional work is required to examine the enterohemolytic phenotype and its associations with the presence of the *ehxA* gene. Second, enterohemolysin can increase the level of the proinflammatory cytokine interleukin-1β in vitro studies [31]; additional studies are warranted to identify the role of enterohemolysin in STEC pathogenesis.

In conclusion, here we describe the prevalence and genetic diversity of *ehxA* gene in clinical STEC isolates collected in Sweden. Our results show that *ehxA* was prevalent in

most of the clinical STEC isolates with high genetic diversity. We found that *ehxA* was often presented in *eae*-positive O157:H7 isolates and isolates from BD patients. Furthermore, *ehxA* subtype B and phylogenetic group II were associated with severe clinical outcomes. Our study suggests that the coexistence of *ehxA*, *eae*, and *stx$_2$* could be used as a risk predictor for severe clinical symptoms in STEC infections.

4. Materials and Methods

4.1. Ethics Statement

The study was approved by the regional ethics committees in Gothenburg (2015/335-15) and Stockholm (2020-02338), Sweden.

4.2. Collection of STEC Isolates

All STEC isolates used in this study were described previously [20]. In total, 239 STEC isolates that were collected from STEC cases from 1994 to 2018 in Sweden were analyzed in this study (Table S4). Bacterial genomic DNA was extracted and sequenced, as previously described [32]. The clinical picture was classified into HUS, BD, and individuals with non-bloody stool (NBS) [33]. Patients were divided into two age groups: <10 years and ≥10 years.

4.3. ehxA Subtyping and Polymorphism Analysis

The complete sequences of the *ehxA* gene were extracted from the genomic assemblies according to the genome annotation. The unique *ehxA* sequences were aligned with reference nucleotide sequences of the previously described *ehxA* subtypes (Table S5). The sequences were aligned and the genetic distances between the *ehxA* subtypes were calculated using the maximum composite likelihood method with MEGA 7.0 software (Center for Evolutionary Medicine and Informatics, Tempe, AZ, USA), and a neighbor-joining tree was generated with 1000 bootstrap resamples. The *ehxA* genotypes based on *ehxA* sequence polymorphism was used to determine the diversity within each *ehxA* subtype.

4.4. Statistical Analyses

The associations between the *ehxA* prevalence or subtypes and bacterial features or clinical outcomes were analyzed using Fisher's exact test. Statistica12 (StatSoft, Inc. Tibco, San Francisco, CA, USA) was used to determine the statistical significance, where *p*-value < 0.05 was considered statistically significant. Multiple testing corrections were done using the Benjamini–Hochberg method when needed.

Author Contributions: Y.H. analysed the data and wrote the manuscript; J.Z. carried out sequence data analysis; C.J., M.C., S.H., and A.F. collected the clinical data and contributed to data analysis; Y.X. assisted in *exhA* gene subtyping and contributed to data interpretation; C.W. contributed to data interpretation; A.M., and X.B. designed the study, supervised the data analysis and writing. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Gothenburg (2015/335-15) and Stockholm (2020-02338), Sweden.

Informed Consent Statement: Patients consent was not required as the clinical data of STEC patients were collected through routine praxis used for the STEC diagnostics and surveillance performed in Sweden in line with local regimens.

Data Availability Statement: The sequences of all strains included in this study are openly available in GenBank with accession numbers and metadata shown in Table S1.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kaper, J.B.; Karmali, M.A. The continuing evolution of a bacterial pathogen. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 4535–4536. [CrossRef]
2. Majowicz, S.; Scallan, E.; Jones-Bitton, A.; Sargeant, J.M.; Stapleton, J.; Angulo, F.J.; Yeung, D.H.; Kirk, M.D. Global Incidence of Human Shiga Toxin–Producing *Escherichia coli* Infections and Deaths: A Systematic Review and Knowledge Synthesis. *Foodborne Pathog. Dis.* **2014**, *11*, 447–455. [CrossRef]
3. Lynn, R.M.; O'Brien, S.J.; Taylor, C.M.; Adak, G.K.; Chart, H.; Cheasty, T.; Coia, J.E.; Gillespie, I.A.; Locking, M.E.; Reilly, W.J.; et al. Childhood Hemolytic Uremic Syndrome, United Kingdom and Ireland. *Emerg. Infect. Dis.* **2005**, *11*, 590–596. [CrossRef] [PubMed]
4. Tarr, P.I.; Gordon, C.A.; Chandler, W.L. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet* **2005**, *365*, 1073–1086. [CrossRef]
5. Scallan, E.; Griffin, P.M.; Angulo, F.J.; Tauxe, R.V.; Hoekstra, R.M. Foodborne Illness Acquired in the United States—Unspecified Agents. *Emerg. Infect. Dis.* **2011**, *17*, 16–22. [CrossRef]
6. Conrad, C.C.; Stanford, K.; McAllister, T.A.; Thomas, J.; Reuter, T. Further development of sample preparation and detection methods for O157 and the top 6 non-O157 STEC serogroups in cattle feces. *J. Microbiol. Methods* **2014**, *105*, 22–30. [CrossRef]
7. Etcheverria, A.I.; Padola, N.L. Shiga toxin-producing *Escherichia coli*: Factors involved in virulence and cattle colonization. *Virulence* **2013**, *4*, 366–372. [CrossRef] [PubMed]
8. Herold, S.; Karch, H.; Schmidt, H. Shiga toxin-encoding bacteriophages—Genomes in motion. *Int. J. Med. Microbiol.* **2004**, *294*, 115–121. [CrossRef] [PubMed]
9. Baranzoni, G.M.; Fratamico, P.; Gangiredla, J.; Patel, I.; Bagi, L.K.; Delannoy, S.; Fach, P.; Boccia, F.; Anastasio, A.; Pepe, T. Characterization of Shiga Toxin Subtypes and Virulence Genes in Porcine Shiga Toxin-Producing *Escherichia coli*. *Front. Microbiol.* **2016**, *7*, 574. [CrossRef] [PubMed]
10. Girard, F.; Batisson, I.; Frankel, G.M.; Harel, J.; Fairbrother, J.M. Interaction of Enteropathogenic and Shiga Toxin-Producing *Escherichia coli* and Porcine Intestinal Mucosa: Role of Intimin and Tir in Adherence. *Infect. Immun.* **2005**, *73*, 6005–6016. [CrossRef] [PubMed]
11. Frankel, G.; Phillips, A.D.; Trabulsi, L.R.; Knutton, S.; Dougan, G.; Matthews, S. Intimin and the host cell—Is it bound to end in Tir(s)? *Trends Microbiol.* **2001**, *9*, 214–218. [CrossRef]
12. Lorenz, S.C.; Son, I.; Maounounen-Laasri, A.; Lin, A.; Fischer, M.; Kase, J.A. Prevalence of Hemolysin Genes and Comparison of *ehxA* Subtype Patterns in Shiga Toxin-Producing *Escherichia coli* (STEC) and Non-STEC Strains from Clinical, Food, and Animal Sources. *Appl. Environ. Microbiol.* **2013**, *20*, 6301–6311. [CrossRef] [PubMed]
13. Beutin, L.; Montenegro, M.A.; Orskov, I.; Orskov, F.; Prada, J.; Zimmermann, S.; Stephan, R. Close association of verotoxin (Shiga-like toxin) production with enterohemolysin production in strains of *Escherichia coli*. *J. Clin. Microbiol.* **1989**, *11*, 2559–2564. [CrossRef] [PubMed]
14. Beutin, L.; Aleksic', S.; Zimmermann, S.; Gleier, K. Virulence factors and phenotypical traits of verotoxigenic strains of *Escherichia coli* isolated from human patients in Germany. *Med. Microbiol. Immunol.* **1994**, *183*, 13–21. [CrossRef]
15. Ethelberg, S.; Olsen, K.E.P.; Scheutz, F.; Jensen, C.; Schiellerup, P.; Engberg, J.; Petersen, A.M.; Olesen, B.; Gerner-Smidt, P.; Mølbak, K. Virulence Factors for Hemolytic Uremic Syndrome, Denmark1. *Emerg. Infect. Dis.* **2004**, *10*, 842–847. [CrossRef]
16. Schwidder, M.; Heinisch, L.; Schmidt, H. Genetics, Toxicity, and Distribution of Enterohemorrhagic *Escherichia coli* Hemolysin. *Toxins* **2019**, *11*, 502. [CrossRef]
17. Cookson, A.L.; Bennett, J.; Thomson-Carter, F.; Attwood, G.T. Molecular Subtyping and Genetic Analysis of the Enterohemolysin Gene (*ehxA*) from Shiga Toxin-Producing *Escherichia coli* and Atypical Enteropathogenic *E. coli*. *Appl. Environ. Microbiol.* **2007**, *73*, 6360–6369. [CrossRef]
18. Patel, I.R.; Gangiredla, J.; Lacher, D.W.; Mammel, M.K.; Bagi, L.; Baranzoni, G.M.; Fratamico, P.M.; Roberts, E.L.; Debroy, C.; Lindsey, R.L.; et al. Interlaboratory Evaluation of the U.S. Food and Drug Administration *Escherichia coli* Identification Microarray for Profiling Shiga Toxin–Producing *Escherichia coli*. *J. Food Prot.* **2018**, *81*, 1275–1282. [CrossRef]

19.　Bai, X.; Mernelius, S.; Jernberg, C.; Einemo, I.-M.; Monecke, S.; Ehricht, R.; Löfgren, S.; Matussek, A. Shiga Toxin-Producing *Escherichia coli* Infection in Jönköping County, Sweden: Occurrence and Molecular Characteristics in Correlation With Clinical Symptoms and Duration of stx Shedding. *Front. Cell. Infect. Microbiol.* **2018**, *8*, 125. [CrossRef]

20.　Fu, S.; Bai, X.; Fan, R.; Sun, H.; Xu, Y.; Xiong, Y. Genetic diversity of the enterohaemolysin gene (*ehxA*) in non-O157 Shiga toxin-producing *Escherichia coli* strains in China. *Sci. Rep.* **2018**, *8*, 1–8. [CrossRef]

21.　Law, D. Virulence factors of *Escherichia coli* O157 and other Shiga toxin-producing *E. coli*. *J. Appl. Microbiol.* **2000**, *88*, 729–745. [CrossRef]

22.　Cookson, A.L.; Croucher, D.; Pope, C.; Bennett, J.; Thomson-Carter, F.; Attwood, G.T. Isolation, Characterization, and Epidemiological Assessment of Shiga Toxin-Producing *Escherichia coli* O84 Isolates from New Zealand. *J. Clin. Microbiol.* **2006**, *44*, 1863–1866. [CrossRef]

23.　Zhang, W.L.; Bielaszewska, M.; Liesegang, A.; Tschäpe, H.; Schmidt, H.; Bitzan, M.; Karch, H. Molecular characteristics and epidemiological significance of Shiga tox-in-producing *Escherichia coli* O26 strains. *J. Clin. Microbiol.* **2000**, *6*, 2134–2140. [CrossRef]

24.　Newton, H.J. Shiga Toxin–producing *Escherichia coli* Strains Negative for Locus of Enterocyte Effacement. *Emerg. Infect. Dis.* **2009**, *15*, 372–380. [CrossRef] [PubMed]

25.　Byrne, L.; Vanstone, G.L.; Perry, N.T.; Launders, N.; Adak, G.K.; Godbole, G.; Grant, K.A.; Smith, R.; Jenkins, C. Epidemiology and microbiology of Shiga toxin-producing *Escherichia coli* other than serogroup O157 in England, 2009–2013. *J. Med. Microbiol.* **2014**, *63*, 1181–1188. [CrossRef] [PubMed]

26.　Haugum, K.; Brandal, L.T.; Lindstedt, B.-A.; Wester, A.L.; Bergh, K.; Afset, J.E. PCR-Based Detection and Molecular Characterization of Shiga Toxin-Producing *Escherichia coli* Strains in a Routine Microbiology Laboratory over 16 years. *J. Clin. Microbiol.* **2014**, *52*, 3156–3163. [CrossRef] [PubMed]

27.　Boerlin, P.; McEwen, S.A.; Boerlin-Petzold, F.; Wilson, J.B.; Johnson, R.P.; Gyles, C.L. Associations between virulence factors of Shiga toxin-producing *Escherichia coli* and disease in humans. *J. Clin. Microbiol.* **1999**, *3*, 497–503. [CrossRef]

28.　Werber, D.; Fruth, A.; Buchholz, U.; Prager, R.; Kramer, M.H.; Ammon, A.; Tschäpe, H. Strong Association Between Shiga Toxin-Producing *Escherichia coli* O157 and Virulence Genes stx_2 and *eae* as Possible Explanation for Predominance of Serogroup O157 in Patients with Haemolytic Uraemic Syndrome. *Eur. J. Clin. Microbiol. Infect. Dis.* **2003**, *22*, 726–730. [CrossRef]

29.　Eklund, M.; Bielaszewska, M.; Nakari, U.-M.; Karch, H.; Siitonen, A. Molecular and phenotypic profiling of sorbitol-fermenting *Escherichia coli* O157:H− human isolates from Finland. *Clin. Microbiol. Infect.* **2006**, *12*, 634–641. [CrossRef] [PubMed]

30.　Schmidt, H.; Karch, H. Enterohemolytic phenotypes and genotypes of shiga toxin-producing *Escherichia coli* O111 strains from patients with diarrhea and hemolytic-uremic syndrome. *J. Clin. Microbiol.* **1996**, *10*, 2364–2367. [CrossRef] [PubMed]

31.　Taneike, I.; Zhang, H.-M.; Wakisaka-Saito, N.; Yamamoto, T. Enterohemolysin operon of Shiga toxin-producing *Escherichia coli*: A virulence function of inflammatory cytokine production from human monocytes. *FEBS Lett.* **2002**, *524*, 219–224. [CrossRef]

32.　Hua, Y.; Bai, X.; Zhang, J.; Jernberg, C.; Chromek, M.; Hansson, S.; Frykman, A.; Yang, X.; Xiong, Y.; Wan, C.; et al. Molecular characteristics of eae-positive clinical Shiga toxin-producing *Escherichia coli* in Sweden. *Emerg. Microbes Infect.* **2020**, *9*, 2562–2570. [CrossRef]

33.　Matussek, A.; Jernberg, C.; Einemo, I.-M.; Monecke, S.; Ehricht, R.; Engelmann, I.; Löfgren, S.; Mernelius, S. Genetic makeup of Shiga toxin-producing *Escherichia coli* in relation to clinical symptoms and duration of shedding: A microarray analysis of isolates from Swedish children. *Eur. J. Clin. Microbiol. Infect. Dis.* **2017**, *36*, 1433–1441. [CrossRef]